Sort   by:  
 Page size 
ProteomicsAllosteric activation of the co-receptor BAK1 by the EFR receptor kinase initiates immune signaling
The structural dynamics of purified wild type and mutant EFR were probed by HDX-MS.
ORGANISM(S): Arabidopsis thaliana (Mouse-ear cress) 
2024-06-27 | PXD049215 | Pride
Hdx-ms Receptor kinase Efr 
ProteomicsDynamics of S752D MuSK kinase domain
The dynamics of purified MuSK S752D kinase domain was probed by HDX-MS.
ORGANISM(S): Homo sapiens (Human) 
2026-08-17 | PXD072130 | Pride
Kinase domain Hdx-ms Musk 
ProteomicsDynamics of wild-type MuSK kinase domain
The dynamics of purified wild-type kinase domain was probed by HDX-MS.
ORGANISM(S): Homo sapiens (Human) 
2026-08-17 | PXD071785 | Pride
Kinase domain Hdx-ms Musk 
ProteomicsStructural basis for the interaction between Drosophila ROS1 and the GPCR BOSS
HDX-MS experiments were performed to identify protein-protein interaction sites.
ORGANISM(S): Drosophila melanogaster (Fruit fly) 
2025-01-22 | PXD051929 | Pride
Weak protein-protein interaction Gpcr Hdx-ms Ros1 Boss 
ProteomicsThe structural dynamics of EGFR exon 19 mutants
Tyrosine kinase inhibitors (TKIs) are used to treat non-small cell lung cancers (NSCLC) driven by epidermal growth factor receptor (EGFR) mutations in the tyrosine kinase domain (TKD). TKI responses vary across tumors driven by the heterogeneous group of exon 19 deletions and mutations, but the mole...
ORGANISM(S): Homo sapiens (Human) 
2023-03-11 | PXD037355 | Pride
Exon 19 Hdx-ms Egfr 
ProteomicsBiochemical and Structural Basif for Differential Inhibitor Sensitivity of EGFR with Distinct Exon 19 Mutaions
Tyrosine kinase inhibitors (TKIs) are used to treat non-small cell lung cancers (NSCLC) driven by epidermal growth factor receptor (EGFR) mutations in the tyrosine kinase domain (TKD). We studied structural basis of differential TKI sensitivity among EGFR exon 19 mutants by HDX-MS.
ORGANISM(S): Homo sapiens (Human) 
2023-03-11 | PXD037374 | Pride
Exon 19 Hdx-ms Egfr 
ProteomicsThe strutural dynamics of EGFR Exon 19 mutants
Tyrosine kinase inhibtors are used to treat non-small cell lung cancers (NSCLC) driven by epidermal growth factor receptor (EGFR) mutations in the tyrosine kinase domain (TKD). We characterized the dynamics of purified EGFR exon 19 kinase domain mutants by HDX-MS with or withour erlotinib, one of th...
ORGANISM(S): Homo sapiens (Human) 
2023-03-11 | PXD037448 | Pride
Hdx-ms Egfr Exon19 
Sort   by:  
 Page size